Two months after announcing the appointment of Nocion Therapeutics CEO Rick Batycky to its board, Pulmatrix has announced a deal with Nocion to look at the use of Pulmatrix’s iSPERSE particle engineering technology for development of inhaled formulations of Nocion drugs. According to the Nocion web site, the company’s lead candidate targets refractory chronic cough.
Pulmatrix CEO Ted Raad said, “This collaboration is an important milestone validating the promise of the iSPERSE platform for research and partnering capabilities. At Pulmatrix, we have successfully applied our technology to improve the delivery of a diverse range of inhaled molecules and believe our approach has the potential to broadly benefit the development and reach of inhaled therapeutics. We are thrilled to enter this collaboration with Nocion and look forward to applying our innovative technology and know how to help them accomplish their goal of advancing promising new candidates that revolutionize the treatment of conditions arising from neurogenic inflammation.”
Batycky commented, “We are excited to be working with Pulmatrix to evaluate the formulatability of our respiratory compounds. The combination of their experienced team, their skill with standard dry powder techniques and their proprietary iSPERSE platform will allow for a thorough evaluation of our compounds to help advance our promising drug candidates.”
Read the Pulmatrix press release.
